Jazz Pharmaceuticals' Ziihera Shows Durable Survival Benefit in HER2+ GEA Trial
Event summary
- Phase 3 HERIZON-GEA-01 trial results published in NEJM show zanidatamab combinations improve PFS and OS in HER2+ GEA.
- Median OS with zanidatamab + tislelizumab + chemotherapy was 26.4 months vs. 19.2 months with trastuzumab + chemotherapy.
- Subgroup analyses show consistent benefits across PD-L1 status, geographic regions, and performance status.
- Jazz submitted data to NCCN for potential inclusion in clinical practice guidelines.
- Additional PD-L1 subgroup analyses to be presented at 2026 ASCO Annual Meeting.
The big picture
Jazz Pharmaceuticals' positive Phase 3 results for zanidatamab in HER2+ gastroesophageal adenocarcinoma (GEA) position the drug as a potential new standard of care. The findings demonstrate durable survival benefits across diverse patient subgroups, including those previously underserved by PD-1 inhibitors. This success could expand Jazz's oncology portfolio and strengthen its competitive position in targeted cancer therapies.
What we're watching
- Regulatory Approval
- Whether the FDA will grant accelerated approval for zanidatamab in first-line HER2+ GEA based on these results.
- Market Adoption
- The pace at which zanidatamab combinations will be adopted as a new standard of care in HER2+ GEA treatment.
- Competitive Positioning
- How these results will position Jazz Pharmaceuticals against competitors in the HER2-targeted oncology space.
Related topics